• Something wrong with this record ?

Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registry

R. Kenney, M. Liu, S. Patil, R. Alroughani, R. Ampapa, R. Bergamaschi, C. Boz, H. Butzkueven, JC. Gomez, E. Cartechini, SE. Madueño, D. Ferraro, F. Grand-Maison, F. Granella, D. Horakova, G. Izquierdo Ayuso, T. Kalincik, J. Lizrova Preiningerova,...

. 2021 ; 430 (-) : 118067. [pub] 20210903

Language English Country Netherlands

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc22003199

BACKGROUND: Short-term outcomes of optic neuritis (ON) have been well characterized. Limited data exists on longer-term visual outcomes in patients who present with ON. The large MSBase registry allows for characterization of long-term visual outcomes after ON. METHODS: Via the MSBase Registry, data on patients from 41 centers was collected during routine clinical and research visits. Physical and visual disability were measured using the expanded disability status scale (EDSS) and the visual function score (VFS). Inclusion criteria for this analysis included age ≥ 18 years, clinically isolated syndrome (CIS), ON-onset, baseline visit within 6 months of onset, and at least one follow-up visit. Survival analysis was used to evaluate the association of disease-modifying treatment with time to conversion to clinically definite MS or sustained EDSS/VFS progression. RESULTS: Data from 60,933 patients were obtained from the MSBase registry in July 2019. Of these, 1317 patients met inclusion criteria; 935 were treated at some point in disease course, while 382 were never treated. At baseline, mean age was 32.3 ± 8.8 years, 74% were female, median EDSS was 2 (IQR 1-2), and median VFS was 1 (IQR 0-2). Median follow-up time was 5.2 years (IQR 2.4-9.3). Treatment was associated with reduced risk and delayed conversion to clinically definite MS (HR = 0.70, p < 0.001), sustained EDSS progression (HR = 0.46, p < 0.0001) and sustained VFS (HR = 0.41, p < 0.001) progression. CONCLUSIONS: In the MSBase cohort, treatment after ON was associated with better visual and neurological outcomes compared to no treatment. These results support early treatment for patients presenting with ON as the first manifestation of MS.

A O S Giuseppe Moscati Avellino Italy

Amiri Hospital Kuwait City Kuwait

Azienda Sanitaria Unica Regionale Marche Ancona Province of Ancona Italy

Bakirkoy Hospital Of Mental Disorders And Neuro Bakirkoy Istanbul Turkey

Centro Internacional de Restauracion Neurologica La Habana Cuba

Charles University Prague and General University Hospital Prague Czech Republic

Cliniques Universitaires Saint Luc UCLouvain Brussels Belgium

Department of Clinical Neuroscience Karolinska Institute Stockholm Sweden

Department of Medical and Surgical Sciences and Advanced Technologies University of Catania Catania Italy

Department of Medicine and Surgery University of Parma Italy

Department of Neurology New York University Grossman School of Medicine New York NY USA

Department of Ophthalmology New York University Grossman School of Medicine New York NY USA

Department of Population Health New York University Grossman School of Medicine New York NY USA

Dipartimento di Scienze Biomediche e Neuromotorie Università di Bologna Bologna Italy

Dokuz eylul uni faculty of medicine Izmir Turkey

Haydarpasa Numune Training and Research Hospital Istanbul Turkey

Hospital Universitario Virgen Macarena Seville Spain

IRCCS Istituto delle Scienze Neurologiche di Bologna Bologna Italy

IRCCS Mondino Foundation Pavia Italy

Johns Hopkins University School of Medicine Baltimore MD USA

KTU Medical Faculty Farabi Hospital Trabzon Turkey

Monash University Melbourne Victoria Australia

MS Centre Royal Melbourne Hospital CORe Department of Medicine University of Melbourne Melbourne AU

MSBase Foundation Alfred Centre Melbourne Australia

Neuro Rive Sud Quebec Canada

Neurologicka Klinika 1 LF UK Prague Czech Republic

Neurologicka Klinika Jihlava Jihlava Czech Republic

Nuovo Ospedale Civile S Agostino Estense Baggiovara MO Italy

Ondokuz Mayis Universitesi Samsun Turkey

University G d'Annunzio Chieti Pescara Italy

University of Modena and Reggio Emilia Modena Province of Modena Italy

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22003199
003      
CZ-PrNML
005      
20220127150559.0
007      
ta
008      
220113s2021 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jns.2021.118067 $2 doi
035    __
$a (PubMed)34537678
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Kenney, Rachel $u Department of Neurology, New York University Grossman School of Medicine, New York, NY, USA; Department of Population Health, New York University Grossman School of Medicine, New York, NY, USA. Electronic address: rachel.kenney@nyulangone.org
245    10
$a Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registry / $c R. Kenney, M. Liu, S. Patil, R. Alroughani, R. Ampapa, R. Bergamaschi, C. Boz, H. Butzkueven, JC. Gomez, E. Cartechini, SE. Madueño, D. Ferraro, F. Grand-Maison, F. Granella, D. Horakova, G. Izquierdo Ayuso, T. Kalincik, J. Lizrova Preiningerova, A. Lugaresi, M. Onofrj, S. Ozakbas, F. Patti, P. Sola, A. Soysal, DLA. Spitaleri, M. Terzi, R. Turkoglu, V. van Pesch, S. Saidha, LE. Thorpe, SL. Galetta, LJ. Balcer, I. Kister, T. Spelman, MSBase Study Group
520    9_
$a BACKGROUND: Short-term outcomes of optic neuritis (ON) have been well characterized. Limited data exists on longer-term visual outcomes in patients who present with ON. The large MSBase registry allows for characterization of long-term visual outcomes after ON. METHODS: Via the MSBase Registry, data on patients from 41 centers was collected during routine clinical and research visits. Physical and visual disability were measured using the expanded disability status scale (EDSS) and the visual function score (VFS). Inclusion criteria for this analysis included age ≥ 18 years, clinically isolated syndrome (CIS), ON-onset, baseline visit within 6 months of onset, and at least one follow-up visit. Survival analysis was used to evaluate the association of disease-modifying treatment with time to conversion to clinically definite MS or sustained EDSS/VFS progression. RESULTS: Data from 60,933 patients were obtained from the MSBase registry in July 2019. Of these, 1317 patients met inclusion criteria; 935 were treated at some point in disease course, while 382 were never treated. At baseline, mean age was 32.3 ± 8.8 years, 74% were female, median EDSS was 2 (IQR 1-2), and median VFS was 1 (IQR 0-2). Median follow-up time was 5.2 years (IQR 2.4-9.3). Treatment was associated with reduced risk and delayed conversion to clinically definite MS (HR = 0.70, p < 0.001), sustained EDSS progression (HR = 0.46, p < 0.0001) and sustained VFS (HR = 0.41, p < 0.001) progression. CONCLUSIONS: In the MSBase cohort, treatment after ON was associated with better visual and neurological outcomes compared to no treatment. These results support early treatment for patients presenting with ON as the first manifestation of MS.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a kohortové studie $7 D015331
650    12
$a demyelinizační nemoci $7 D003711
650    _2
$a posuzování pracovní neschopnosti $7 D004185
650    _2
$a progrese nemoci $7 D018450
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    12
$a roztroušená skleróza $x komplikace $x diagnóza $x epidemiologie $7 D009103
650    12
$a zánět zrakového nervu $x diagnóza $x epidemiologie $7 D009902
650    _2
$a registrace $7 D012042
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
700    1_
$a Liu, Mengling $u Department of Population Health, New York University Grossman School of Medicine, New York, NY, USA. Electronic address: mengling.liu@nyulangone.org
700    1_
$a Patil, Sachi $u Department of Neurology, New York University Grossman School of Medicine, New York, NY, USA. Electronic address: sachi.patil@nyulangone.org
700    1_
$a Alroughani, Raed $u Amiri Hospital, Kuwait City, Kuwait
700    1_
$a Ampapa, Radek $u Neurologicka Klinika Jihlava, Jihlava, Czech Republic
700    1_
$a Bergamaschi, Roberto $u IRCCS Mondino Foundation, Pavia, Italy. Electronic address: roberto.bergamaschi@mondino.it
700    1_
$a Boz, Cavit $u KTU Medical Faculty Farabi Hospital, Trabzon, Turkey
700    1_
$a Butzkueven, Helmut $u Monash University, Melbourne, Victoria, Australia. Electronic address: helmut.butzkueven@monash.edu
700    1_
$a Gomez, Jose Cabrera $u Centro Internacional de Restauracion Neurologica, La Habana, Cuba. Electronic address: cabrera.gomez@infomed.sld.cu
700    1_
$a Cartechini, Elisabetta $u Azienda Sanitaria Unica Regionale Marche, Ancona, Province of Ancona, Italy. Electronic address: elisabetta.cartechini@sanita.marche.it
700    1_
$a Madueño, Sara Eichau $u Hospital Universitario Virgen Macarena, Seville, Spain
700    1_
$a Ferraro, Diana $u University of Modena and Reggio Emilia, Modena, Province of Modena, Italy. Electronic address: diana.ferraro@unimore.it
700    1_
$a Grand-Maison, Francois $u Neuro Rive-Sud, Quebec, Canada
700    1_
$a Granella, Franco $u Department of Medicine and Surgery, University of Parma, Italy. Electronic address: franco.granella@unipr.it
700    1_
$a Horakova, Dana $u Charles University in Prague and General University Hospital, Prague, Czech Republic. Electronic address: Dana.Horakova@vfn.cz
700    1_
$a Izquierdo Ayuso, Guillermo $u Hospital Universitario Virgen Macarena, Seville, Spain. Electronic address: gia@us.es
700    1_
$a Kalincik, Tomas $u MS Centre, Royal Melbourne Hospital, CORe, Department of Medicine, University of Melbourne, Melbourne, AU. Electronic address: tomas.kalincik@unimelb.edu.au
700    1_
$a Lizrova Preiningerova, Jana $u Neurologicka Klinika 1 LF UK, Prague, Czech Republic. Electronic address: jana.lizrova@vfn.cz
700    1_
$a Lugaresi, Alessandra $u IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy; Dipartimento di Scienze Biomediche e Neuromotorie, Università di Bologna, Bologna, Italy. Electronic address: alessandra.lugaresi2@unibo.it
700    1_
$a Onofrj, Marco $u University G. d'Annunzio, Chieti-Pescara, Italy. Electronic address: onofrj@unich.it
700    1_
$a Ozakbas, Serkan $u Dokuz eylul uni. faculty of medicine, Izmir, Turkey
700    1_
$a Patti, Francesco $u Department of Medical and Surgical Sciences and Advanced Technologies, University of Catania, Catania, Italy. Electronic address: patti@unict.it
700    1_
$a Sola, Patrizia $u Nuovo Ospedale Civile S. Agostino-Estense, Baggiovara, MO, Italy. Electronic address: sola.patrizia@aou.mo.it
700    1_
$a Soysal, Aysun $u Bakirkoy Hospital Of Mental Disorders And Neuro, Bakirkoy/Istanbul, Turkey
700    1_
$a Spitaleri, Daniele Litterio A $u A.O. "S. Giuseppe Moscati", Avellino, Italy
700    1_
$a Terzi, Murat $u Ondokuz Mayis Universitesi, Samsun, Turkey. Electronic address: mterzi@omu.edu.tr
700    1_
$a Turkoglu, Recai $u Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey
700    1_
$a van Pesch, Vincent $u Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium. Electronic address: vincent.vanpesch@clin.ucl.ac.be
700    1_
$a Saidha, Shiv $u Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: ssaidha2@jhmi.edu
700    1_
$a Thorpe, Lorna E $u Department of Population Health, New York University Grossman School of Medicine, New York, NY, USA. Electronic address: Lorna.Thorpe@nyulangone.org
700    1_
$a Galetta, Steven L $u Department of Neurology, New York University Grossman School of Medicine, New York, NY, USA; Department of Ophthalmology, New York University Grossman School of Medicine, New York, NY, USA. Electronic address: Steven.Galetta@nyulangone.org
700    1_
$a Balcer, Laura J $u Department of Neurology, New York University Grossman School of Medicine, New York, NY, USA; Department of Population Health, New York University Grossman School of Medicine, New York, NY, USA; Department of Ophthalmology, New York University Grossman School of Medicine, New York, NY, USA. Electronic address: laura.balcer@nyulangone.org
700    1_
$a Kister, Ilya $u Department of Neurology, New York University Grossman School of Medicine, New York, NY, USA. Electronic address: Ilya.Kister@nyulangone.org
700    1_
$a Spelman, Tim $u MSBase Foundation, Alfred Centre, Melbourne, Australia; Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden. Electronic address: tim@burnet.edu.au
710    2_
$a MSBase Study Group
773    0_
$w MED00003004 $t Journal of the neurological sciences $x 1878-5883 $g Roč. 430, č. - (2021), s. 118067
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34537678 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127150556 $b ABA008
999    __
$a ok $b bmc $g 1750840 $s 1154348
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 430 $c - $d 118067 $e 20210903 $i 1878-5883 $m Journal of the neurological sciences $n J Neurol Sci $x MED00003004
LZP    __
$a Pubmed-20220113

Find record

Citation metrics

Archiving options